{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:35:51Z","timestamp":1792805751355,"version":"4.5.0"},"reference-count":206,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Korea Ministry of Education","doi-asserted-by":"publisher","award":["2025-RISE-11-014-03"],"award-info":[{"award-number":["2025-RISE-11-014-03"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB036493"],"award-info":[{"award-number":["R01EB036493"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI190578"],"award-info":[{"award-number":["R21AI190578"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21NS132018"],"award-info":[{"award-number":["R21NS132018"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AG093031"],"award-info":[{"award-number":["R21AG093031"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS138455"],"award-info":[{"award-number":["R01NS138455"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG080016"],"award-info":[{"award-number":["R01AG080016"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.addr.2026.115778","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:12:13Z","timestamp":1768493533000},"page":"115778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system"],"prefix":"10.1016","volume":"230","author":[{"given":"Hye Jin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin F.","family":"Greineder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther."},{"issue":"18","key":"10.1016\/j.addr.2026.115778_bb0010","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.addr.2026.115778_bb0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.addr.2026.115778_bb0020","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.addr.2026.115778_bb0025","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nbt1016-1002","article-title":"Big win possible for Ionis\/Biogen antisense drug in muscular atrophy","volume":"34","author":"Garber","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.addr.2026.115778_bb0030","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s10072-025-07994-2","article-title":"Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"46","author":"Hamad","year":"2025","journal-title":"Neurol. Sci."},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0035","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.2174\/1570159X19666210402104054","article-title":"siRNA therapeutics: future promise for neurodegenerative diseases","volume":"19","author":"Amiri","year":"2021","journal-title":"Curr. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.addr.2026.115778_bb0040","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.ymthe.2018.04.010","article-title":"Aptamer-based control of gene expression utilizing endogenous miRNAs","volume":"26","author":"Hartig","year":"2018","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10565-022-09761-x","article-title":"The role of microRNAs in neurodegenerative diseases: a review","volume":"39","author":"Li","year":"2023","journal-title":"Cell Biol. Toxicol."},{"issue":"6","key":"10.1016\/j.addr.2026.115778_bb0050","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.addr.2026.115778_bb0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0065","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/nar\/gkad023","article-title":"Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics","volume":"51","author":"Finicle","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"20","key":"10.1016\/j.addr.2026.115778_bb0070","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129240","article-title":"Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging","volume":"4","author":"Mazur","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bjae.2019.11.002","article-title":"Complications associated with intrathecal drug delivery systems","volume":"20","author":"Delhaas","year":"2020","journal-title":"BJA Educ."},{"key":"10.1016\/j.addr.2026.115778_bb0080","article-title":"Intrathecal drug delivery: advances and applications in the management of chronic pain patient","volume":"3","author":"De Andres","year":"2022","journal-title":"Front. Pain Res. (Lausanne)"},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102359","article-title":"Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of ca2+ and Mg2+ in the formulation","volume":"35","author":"Miller","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"14","key":"10.1016\/j.addr.2026.115778_bb0090","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/0008-5472.CAN-12-0128","article-title":"Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques","volume":"72","author":"McDannold","year":"2012","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027877","article-title":"Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood-brain barrier","volume":"6","author":"Burgess","year":"2011","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.addr.2026.115778_bb0100","article-title":"Gene therapy for spinal muscular atrophy (SMA): a review of current challenges and safety considerations for Onasemnogene Abeparvovec (Zolgensma)","volume":"15","author":"Ogbonmide","year":"2023","journal-title":"Cureus"},{"issue":"18","key":"10.1016\/j.addr.2026.115778_bb0105","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"issue":"17","key":"10.1016\/j.addr.2026.115778_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178282","article-title":"AAV-based gene therapy: opportunities, risks, and scale-up strategies","volume":"26","author":"Moldavskii","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.addr.2026.115778_bb0120","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV gene transfer to the nervous system: a clinical reality","volume":"101","author":"Hudry","year":"2019","journal-title":"Neuron"},{"issue":"21","key":"10.1016\/j.addr.2026.115778_bb0125","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1002\/anie.201914751","article-title":"Systemic brain delivery of antisense oligonucleotides across the blood-brain barrier with a glucose-coated polymeric nanocarrier","volume":"59","author":"Min","year":"2020","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2026.115778_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.887678","article-title":"Lipid nanoparticles for antisense oligonucleotide gene interference into brain border-associated macrophages","volume":"9","author":"Calero","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020760","article-title":"Nanocarriers for delivery of oligonucleotides to the CNS","volume":"23","author":"Male","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.addr.2026.115778_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ph17081070","article-title":"Advances in intrathecal nanoparticle delivery: targeting the blood-cerebrospinal fluid barrier for enhanced CNS drug delivery","volume":"17","author":"Madadi","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.addr.2026.115778_bb0145","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.addr.2015.02.007","article-title":"Delivery of oligonucleotides with lipid nanoparticles","volume":"87","author":"Wang","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0150","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1021\/acs.bioconjchem.8b00761","article-title":"Bioconjugated oligonucleotides: recent developments and therapeutic applications","volume":"30","author":"Benizri","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"10","key":"10.1016\/j.addr.2026.115778_bb0155","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1021\/acs.bioconjchem.9b00306","article-title":"Antibody-oligonucleotide conjugates as therapeutic, imaging, and detection agents","volume":"30","author":"Dovgan","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"12","key":"10.1016\/j.addr.2026.115778_bb0160","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.2174\/138920112803341833","article-title":"Targeting the brain: advances in drug delivery","volume":"13","author":"Blumling Iii","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"10","key":"10.1016\/j.addr.2026.115778_bb0165","doi-asserted-by":"crossref","first-page":"11031","DOI":"10.3390\/cimb46100655","article-title":"Peptide-oligonucleotide conjugation: chemistry and therapeutic applications","volume":"46","author":"Malinowska","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","article-title":"Targeting strategies for tissue-specific drug delivery","volume":"181","author":"Zhao","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.addr.2026.115778_bb0175","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/nsr\/nwaa161","article-title":"Lipid-oligonucleotide conjugates for bioapplications","volume":"7","author":"Li","year":"2020","journal-title":"Natl. Sci. Rev."},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020320","article-title":"Lipid and peptide-oligonucleotide conjugates for therapeutic purposes: from simple hybrids to complex multifunctional assemblies","volume":"15","author":"Fabrega","year":"2023","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0185","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1134\/S0006297923110111","article-title":"Cell-penetrating peptides as vehicles for delivery of therapeutic nucleic acids. Mechanisms and application in medicine","volume":"88","author":"Timotievich","year":"2023","journal-title":"Biochemistry (Mosc)"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12272-022-01425-y","article-title":"Recent advances in selective and targeted drug\/gene delivery systems using cell-penetrating peptides","volume":"46","author":"Nam","year":"2023","journal-title":"Arch. Pharm. Res."},{"issue":"3","key":"10.1016\/j.addr.2026.115778_bb0195","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/nat.2016.0652","article-title":"Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy","volume":"27","author":"Shabanpoor","year":"2017","journal-title":"Nucleic Acid Ther."},{"issue":"9","key":"10.1016\/j.addr.2026.115778_bb0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jlcr.4023","article-title":"Peptides for trans-blood-brain barrier delivery","volume":"66","author":"Blades","year":"2023","journal-title":"J. Labelled Comp. Radiopharm."},{"issue":"17","key":"10.1016\/j.addr.2026.115778_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26175420","article-title":"Chemistry of peptide-oligonucleotide conjugates: a review","volume":"26","author":"Klabenkova","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115778_bb0210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.addr.2015.02.008","article-title":"Delivery of therapeutic oligonucleotides with cell penetrating peptides","volume":"87","author":"Boisguerin","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115778_bb0215","doi-asserted-by":"crossref","first-page":"12294","DOI":"10.1038\/ncomms12294","article-title":"Peptide-oligonucleotide conjugates as nanoscale building blocks for assembly of an artificial three-helix protein mimic","volume":"7","author":"Lou","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020290","article-title":"Intranasal delivery of anti-apoptotic siRNA complexed with Fas-Signaling blocking peptides attenuates cellular apoptosis in brain ischemia","volume":"16","author":"Chung","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115778_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125198","article-title":"To conjugate or not to conjugate? Evaluating the potential use of cell-penetrating peptides for conjugation or complexation with oligonucleotides by surface plasmon resonance","volume":"671","author":"Dueholm","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119455","article-title":"Peptide-based nanoparticles for systemic extrahepatic delivery of therapeutic nucleotides","volume":"24","author":"Wickline","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.addr.2026.115778_bb0235","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1021\/acs.biomac.2c00767","article-title":"Designing synthetic polymers for nucleic acid complexation and delivery: from polyplexes to Micelleplexes to triggered degradation","volume":"23","author":"Zhou","year":"2022","journal-title":"Biomacromolecules"},{"issue":"3","key":"10.1016\/j.addr.2026.115778_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102227","article-title":"A novel multitargeted self-assembling peptide-siRNA complex for simultaneous inhibition of SARS-CoV-2-host cell interaction and replication","volume":"35","author":"Tuttolomondo","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041130","article-title":"Enhancing the effectiveness of oligonucleotide therapeutics using cell-penetrating peptide conjugation, chemical modification, and carrier-based delivery strategies","volume":"15","author":"Anwar","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0250","doi-asserted-by":"crossref","first-page":"12740","DOI":"10.1038\/s41598-018-31096-z","article-title":"Characterization of membrane penetration and cytotoxicity of C9orf72-encoding arginine-rich dipeptides","volume":"8","author":"Kanekura","year":"2018","journal-title":"Sci. Rep."},{"issue":"39","key":"10.1016\/j.addr.2026.115778_bb0255","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115778_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120398","article-title":"Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides","volume":"599","author":"Dastpeyman","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115778_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","article-title":"Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics","volume":"203","author":"Lorenzer","year":"2015","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0270","first-page":"379","article-title":"Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues","volume":"77","author":"Butler","year":"1997","journal-title":"Lab. Investig."},{"issue":"5990","key":"10.1016\/j.addr.2026.115778_bb0275","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/312162a0","article-title":"Transferrin receptor on endothelium of brain capillaries","volume":"312","author":"Jefferies","year":"1984","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.addr.2026.115778_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002469","article-title":"A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier","volume":"3","author":"Karkan","year":"2008","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.addr.2026.115778_bb0285","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1177\/0271678X18772998","article-title":"A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a preclinical model","volume":"39","author":"Thom","year":"2019","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.addr.2026.115778_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.596976","article-title":"Discovery of a highly conserved peptide in the Iron transporter melanotransferrin that traverses an intact blood brain barrier and localizes in neural cells","volume":"15","author":"Singh","year":"2021","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0295","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1083\/jcb.138.4.877","article-title":"A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier","volume":"138","author":"Dehouck","year":"1997","journal-title":"J. Cell Biol."},{"issue":"5","key":"10.1016\/j.addr.2026.115778_bb0300","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1096\/fj.201600827R","article-title":"Use of LDL receptor-targeting peptide vectors for in vitro and in vivo cargo transport across the blood-brain barrier","volume":"31","author":"Molino","year":"2017","journal-title":"FASEB J."},{"issue":"18","key":"10.1016\/j.addr.2026.115778_bb0305","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1073\/pnas.0702170104","article-title":"Targeted delivery of proteins across the blood-brain barrier","volume":"104","author":"Spencer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0310","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1074\/jbc.M115.678185","article-title":"Systemic central nervous system (CNS)-targeted delivery of neuropeptide Y (NPY) reduces neurodegeneration and increases neural precursor cell proliferation in a mouse model of Alzheimer disease","volume":"291","author":"Spencer","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0315","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00401-018-1869-0","article-title":"Selective targeting of 3 repeat tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders","volume":"136","author":"Spencer","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.addr.2026.115778_bb0320","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nbd.2019.03.001","article-title":"Systemic peptide mediated delivery of an siRNA targeting alpha-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease","volume":"127","author":"Spencer","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.addr.2026.115778_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116737","article-title":"Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide","volume":"175","author":"Yeoh","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0330","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11095-022-03433-5","article-title":"CNS delivery of nucleic acid therapeutics: beyond the blood-brain barrier and towards specific cellular targeting","volume":"40","author":"D'Souza","year":"2023","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.addr.2026.115778_bb0335","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/jgm.1062","article-title":"Neuron-specific delivery of nucleic acids mediated by Tet1-modified poly(ethylenimine)","volume":"9","author":"Park","year":"2007","journal-title":"J. Gene Med."},{"issue":"7149","key":"10.1016\/j.addr.2026.115778_bb0340","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nature05901","article-title":"Transvascular delivery of small interfering RNA to the central nervous system","volume":"448","author":"Kumar","year":"2007","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.addr.2026.115778_bb0345","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1039\/D1RA00550B","article-title":"Application progress of RVG peptides to facilitate the delivery of therapeutic agents into the central nervous system","volume":"11","author":"Wang","year":"2021","journal-title":"RSC Adv."},{"issue":"9","key":"10.1016\/j.addr.2026.115778_bb0350","doi-asserted-by":"crossref","first-page":"11159","DOI":"10.1021\/acsami.3c14908","article-title":"Cell-penetrating and enzyme-responsive peptides for targeted Cancer therapy: role of arginine residue length on cell penetration and in vivo systemic toxicity","volume":"16","author":"Ghaemi","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0355","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/mt.2008.215","article-title":"A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells","volume":"17","author":"Crombez","year":"2009","journal-title":"Mol. Ther."},{"issue":"15","key":"10.1016\/j.addr.2026.115778_bb0360","doi-asserted-by":"crossref","first-page":"8471","DOI":"10.1021\/acs.jmedchem.0c00840","article-title":"Targeted delivery of antisense oligonucleotides using neurotensin peptides","volume":"63","author":"Nikan","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0898-6568(00)00130-3","article-title":"Sortilin\/neurotensin receptor-3: a new tool to investigate neurotensin signaling and cellular trafficking?","volume":"13","author":"Mazella","year":"2001","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0370","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12951-025-03277-2","article-title":"Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?","volume":"23","author":"Wang","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"12","key":"10.1016\/j.addr.2026.115778_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13122065","article-title":"Protease-resistant peptides for targeting and intracellular delivery of therapeutics","volume":"13","author":"Lucana","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115778_bb0380","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/bs.apha.2014.06.004","article-title":"Delivery of therapeutic peptides and proteins to the CNS","volume":"71","author":"Salameh","year":"2014","journal-title":"Adv. Pharmacol."},{"issue":"10","key":"10.1016\/j.addr.2026.115778_bb0385","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.bmc.2017.09.011","article-title":"Therapeutic peptides for CNS indications: Progress and challenges","volume":"26","author":"Morimoto","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0390","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1602\/neurorx.2.1.44","article-title":"Development of neuropeptide drugs that cross the blood-brain barrier","volume":"2","author":"Egleton","year":"2005","journal-title":"NeuroRx"},{"issue":"20","key":"10.1016\/j.addr.2026.115778_bb0395","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1093\/nar\/gkn541","article-title":"Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies","volume":"36","author":"Abes","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0400","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate","volume":"18","author":"Amantana","year":"2007","journal-title":"Bioconjug. Chem."},{"issue":"9","key":"10.1016\/j.addr.2026.115778_bb0405","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112546119","article-title":"Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy","volume":"119","author":"Lim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"19","key":"10.1016\/j.addr.2026.115778_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/cells12192395","article-title":"Enhancing antisense oligonucleotide-based therapeutic delivery with DG9, a versatile cell-penetrating peptide","volume":"12","author":"Haque","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0415","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1038\/s41467-025-59494-8","article-title":"DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function","volume":"16","author":"Shah","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0420","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s42003-022-03132-2","article-title":"Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides","volume":"5","author":"Bost","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.addr.2026.115778_bb0425","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.omtn.2023.06.022","article-title":"The endosomal escape vehicle platform enhances delivery of oligonucleotides in preclinical models of neuromuscular disorders","volume":"33","author":"Li","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0430","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/1061186X.2016.1258566","article-title":"Trileucine residues in a ligand-CPP-based siRNA delivery platform improve endosomal escape of siRNA","volume":"25","author":"Ullah","year":"2017","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2026.115778_bb0435","first-page":"181","article-title":"Stimuli-responsive peptide assemblies: design, self-assembly, modulation, and biomedical applications","volume":"35","author":"Mu","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.addr.2026.115778_bb0440","doi-asserted-by":"crossref","first-page":"11517","DOI":"10.2147\/IJN.S483252","article-title":"Stimuli-responsive peptide\/siRNA nanoparticles as a radiation sensitizer for glioblastoma treatment by co-inhibiting RELA\/P65 and EGFR","volume":"19","author":"Cen","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"7","key":"10.1016\/j.addr.2026.115778_bb0445","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/mt.2011.79","article-title":"Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice","volume":"19","author":"Yin","year":"2011","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.addr.2026.115778_bb0450","article-title":"Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0455","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1172\/JCI128205","article-title":"Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice","volume":"129","author":"Klein","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.addr.2026.115778_bb0460","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.ymthe.2021.11.012","article-title":"Cell-penetrating peptide-conjugated morpholino rescues SMA in a symptomatic preclinical model","volume":"30","author":"Bersani","year":"2022","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.addr.2026.115778_bb0465","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160516","article-title":"DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration","volume":"8","author":"Aslesh","year":"2023","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.addr.2026.115778_bb0470","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1515\/CCLM.2011.077","article-title":"Alpha-synuclein in Parkinson disease and other neurodegenerative disorders","volume":"49","author":"Eller","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"issue":"3","key":"10.1016\/j.addr.2026.115778_bb0475","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","article-title":"Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry","volume":"10","author":"Hamilton","year":"2000","journal-title":"Brain Pathol."},{"key":"10.1016\/j.addr.2026.115778_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106285","article-title":"Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce alpha-synuclein in a mouse model of Alzheimer's disease","volume":"186","author":"Leitao","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.addr.2026.115778_bb0485","article-title":"Oxidative injury in ischemic stroke: a focus on NADPH oxidase 4","volume":"2022","author":"Li","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.addr.2026.115778_bb0490","article-title":"A Nanomule peptide carrier delivers siRNA across the intact blood-brain barrier to attenuate ischemic stroke","volume":"8","author":"Eyford","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.addr.2026.115778_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107469","article-title":"Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): current status and future perspectives","volume":"209","author":"Jiao","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.addr.2026.115778_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126442","article-title":"Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives","volume":"22","author":"Kouhi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10040838","article-title":"Antibody-oligonucleotide conjugates: a twist to antibody-drug conjugates","volume":"10","author":"Dugal-Tessier","year":"2021","journal-title":"J. Clin. Med."},{"issue":"17","key":"10.1016\/j.addr.2026.115778_bb0510","doi-asserted-by":"crossref","first-page":"14852","DOI":"10.1021\/acs.jmedchem.4c00802","article-title":"Structure-activity relationship of antibody-oligonucleotide conjugates: evaluating bioconjugation strategies for antibody-siRNA conjugates for drug development","volume":"67","author":"Cochran","year":"2024","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0515","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1007\/s11095-014-1596-8","article-title":"Methods to make homogenous antibody drug conjugates","volume":"32","author":"Kline","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115778_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2022.100128","article-title":"Antibody\u2013siRNA conjugates (ARC): emerging siRNA drug formulation","volume":"15","author":"Cao","year":"2022","journal-title":"Med. Drug Discov."},{"issue":"6","key":"10.1016\/j.addr.2026.115778_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12060545","article-title":"Development of antibody-oligonucleotide complexes for targeting Exosomal MicroRNA","volume":"12","author":"Yamayoshi","year":"2020","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0530","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.4049\/jimmunol.1403012","article-title":"A new approach for the treatment of arthritis in mice with a novel conjugate of an anti-C5aR1 antibody and C5 small interfering RNA","volume":"194","author":"Mehta","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2026.115778_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.124847","article-title":"Immobilization of biotinylated antibodies through streptavidin binding aptamer","volume":"265","author":"Brambilla","year":"2023","journal-title":"Talanta"},{"issue":"3","key":"10.1016\/j.addr.2026.115778_bb0540","article-title":"Self-assembled antibody-oligonucleotide conjugates for targeted delivery of complementary antisense oligonucleotides","volume":"64","author":"Zhou","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0545","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/npp.2011.196","article-title":"Transferrin antibodies into the brain","volume":"37","author":"Dennis","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"760","key":"10.1016\/j.addr.2026.115778_bb0550","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2245","article-title":"Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier","volume":"16","author":"Barker","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"24","key":"10.1016\/j.addr.2026.115778_bb0555","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154142","article-title":"Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy","volume":"7","author":"Hammond","year":"2022","journal-title":"JCI Insight"},{"issue":"6760","key":"10.1016\/j.addr.2026.115778_bb0560","doi-asserted-by":"crossref","DOI":"10.1126\/science.ads3204","article-title":"Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA","volume":"389","author":"Pizzo","year":"2025","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0565","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41467-025-57108-x","article-title":"Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution","volume":"16","author":"Khoury","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0570","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1874121","article-title":"Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis","volume":"13","author":"Chang","year":"2021","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101476","article-title":"Harnessing synaptic vesicle release and recycling with antibody shuttle for targeted delivery of therapeutics to neurons","volume":"33","author":"Yee","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0580","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1038\/s41467-023-40681-4","article-title":"CD98hc is a target for brain delivery of biotherapeutics","volume":"14","author":"Chew","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0585","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.chembiol.2023.09.008","article-title":"Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs","volume":"31","author":"Pornnoppadol","year":"2024","journal-title":"Cell Chem. Biol."},{"issue":"12","key":"10.1016\/j.addr.2026.115778_bb0590","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.medj.2022.09.007","article-title":"Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis","volume":"3","author":"Edavettal","year":"2022","journal-title":"Med"},{"issue":"7","key":"10.1016\/j.addr.2026.115778_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071452","article-title":"Brain delivery of IGF1R5, a single-domain antibody targeting insulin-like growth Factor-1 receptor","volume":"14","author":"Yogi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0600","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1038\/s41598-021-83198-w","article-title":"Defining the epitope of a blood-brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor","volume":"11","author":"Sheff","year":"2021","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0605","article-title":"Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier","volume":"2","author":"Shin","year":"2022","journal-title":"Cell Rep. Methods"},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0610","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.sbi.2010.01.010","article-title":"An intracellular traffic jam: fc receptor-mediated transport of immunoglobulin G","volume":"20","author":"Tesar","year":"2010","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.addr.2026.115778_bb0615","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978513","article-title":"Applications of nanobodies in brain diseases","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0620","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2410968","article-title":"Single domain antibody-scFv conjugate targeting amyloid beta and TfR penetrates the blood-brain barrier and interacts with amyloid beta","volume":"16","author":"Faresjo","year":"2024","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00492","article-title":"Lowering the affinity of single-chain monovalent BBB shuttle scFc-scFv8D3 prolongs its half-life and increases brain concentration","volume":"22","author":"Rosa","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0630","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0635","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11095-025-03829-z","article-title":"Nanobody-oligonucleotide conjugates (NucleoBodies): the next frontier in oligonucleotide therapy","volume":"42","author":"Tripathy","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115778_bb0640","unstructured":"R. Cohen, M. David, G. Jacouot, J. Temsamani, P. Lecorche, M. Khrestchatisky, Transferrin receptor-binding molecules, conjugates thereof and their uses, Patent Application No. US20230414780A1, 2023."},{"issue":"20","key":"10.1016\/j.addr.2026.115778_bb0645","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf487","article-title":"Improved targeted delivery of antisense oligonucleotide with an antibody mask","volume":"53","author":"Hsia","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"84","key":"10.1016\/j.addr.2026.115778_bb0650","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"545","key":"10.1016\/j.addr.2026.115778_bb0655","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1359","article-title":"Brain delivery of therapeutic proteins using an fc fragment blood-brain barrier transport vehicle in mice and monkeys","volume":"12","author":"Kariolis","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"19","key":"10.1016\/j.addr.2026.115778_bb0660","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145445","article-title":"Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of hunter syndrome","volume":"6","author":"Arguello","year":"2021","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.addr.2026.115778_bb0665","first-page":"416","article-title":"A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models","volume":"26","author":"van Lengerich","year":"2023","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0670","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20131660","article-title":"Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants","volume":"211","author":"Bien-Ly","year":"2014","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0675","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/j.pain.0000000000000810","article-title":"Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti-transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity","volume":"158","author":"Webster","year":"2017","journal-title":"Pain"},{"issue":"17","key":"10.1016\/j.addr.2026.115778_bb0680","doi-asserted-by":"crossref","first-page":"14868","DOI":"10.1021\/acs.jmedchem.4c00803","article-title":"Structure-activity relationship of antibody-oligonucleotide conjugates: evaluating bioconjugation strategies for antibody-Phosphorodiamidate morpholino oligomer conjugates for drug development","volume":"67","author":"Cochran","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.addr.2026.115778_bb0685","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0690","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1021\/acs.molpharmaceut.1c00473","article-title":"Chemical site-specific conjugation platform to improve the pharmacokinetics and therapeutic index of antibody-drug conjugates","volume":"18","author":"Matsuda","year":"2021","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.addr.2026.115778_bb0695","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.xphs.2023.12.003","article-title":"Agitation-induced aggregation of lysine- and interchain cysteine-linked antibody-drug conjugates","volume":"113","author":"Johann","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.addr.2026.115778_bb0700","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/acs.molpharmaceut.6b00995","article-title":"Efficient preparation of site-specific antibody-drug conjugates using cysteine insertion","volume":"14","author":"Dimasi","year":"2017","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/ph14040343","article-title":"Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches","volume":"14","author":"Hussain","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"18","key":"10.1016\/j.addr.2026.115778_bb0710","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24183287","article-title":"Site selective antibody-oligonucleotide conjugation via microbial transglutaminase","volume":"24","author":"Huggins","year":"2019","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0715","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttle amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"mAbs"},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0720","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1021\/acs.bioconjchem.3c00393","article-title":"Diligent design enables antibody-ASO conjugates with optimal pharmacokinetic properties","volume":"34","author":"Sela","year":"2023","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"10.1016\/j.addr.2026.115778_bb0725","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2026.115778_bb0730","unstructured":"Alam R, A.A., Andrews FH, Babb NA, Balasubramaniam D, Cortez GS, Croy JE, Driver DA, Fellows RE, Girard D, Chauvigne-Hines L, Liu F, Tani H, Gonzalez Valcarcel IC, Lawrence SA, Hosahalli Kulkarni N, York JS, Transferrin receptor binding proteins and conjugates. US Patent Application No. US20240059784A1. 2024."},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0735","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020342","article-title":"Delivery of oligonucleotides: efficiency with lipid conjugation and clinical outcome","volume":"14","author":"Tran","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0740","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/s41467-024-45609-0","article-title":"Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy","volume":"15","author":"Hoogenboezem","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.addr.2026.115778_bb0745","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acs.molpharmaceut.6b01027","article-title":"Lipid-drug conjugate for enhancing drug delivery","volume":"14","author":"Irby","year":"2017","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.addr.2026.115778_bb0750","article-title":"Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain","volume":"5","author":"Nikan","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0755","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1529\/biophysj.103.033480","article-title":"Nanostructure of cationic lipid-oligonucleotide complexes","volume":"87","author":"Weisman","year":"2004","journal-title":"Biophys. J."},{"issue":"5","key":"10.1016\/j.addr.2026.115778_bb0760","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051435","article-title":"Versatility of liposomes for antisense oligonucleotide delivery: a special focus on various therapeutic areas","volume":"15","author":"Gupta","year":"2023","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0765","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115778_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121645","article-title":"An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy","volume":"287","author":"Liu","year":"2022","journal-title":"Biomaterials"},{"issue":"14","key":"10.1016\/j.addr.2026.115778_bb0775","doi-asserted-by":"crossref","first-page":"13594","DOI":"10.1021\/acsnano.3c02268","article-title":"Ionizable lipid nanoparticles for Therapeutic Base editing of congenital brain disease","volume":"17","author":"Palanki","year":"2023","journal-title":"ACS Nano"},{"issue":"33","key":"10.1016\/j.addr.2026.115778_bb0780","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adw0730","article-title":"Lipid nanoparticles for mRNA delivery in brain via systemic administration","volume":"11","author":"Cao","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115778_bb0785","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.omtn.2023.05.005","article-title":"Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection","volume":"32","author":"Byrnes","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"17","key":"10.1016\/j.addr.2026.115778_bb0790","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1093\/nar\/19.17.4695","article-title":"Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution","volume":"19","author":"de Smidt","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2026.115778_bb0795","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jconrel.2025.02.025","article-title":"Pharmacokinetics and protein binding of cholesterol-conjugated heteroduplex oligonucleotide","volume":"380","author":"Yoshioka","year":"2025","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb0800","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/jpet.302.2.619","article-title":"Bis-cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver","volume":"302","author":"Bijsterbosch","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.addr.2026.115778_bb0805","article-title":"Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain","volume":"4","author":"Alterman","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"43","key":"10.1016\/j.addr.2026.115778_bb0810","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.addr.2026.115778_bb0815","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41587-021-00972-x","article-title":"Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS","volume":"39","author":"Nagata","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0820","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/jpet.122.001331","volume":"384","author":"Goto","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.addr.2026.115778_bb0825","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.addr.2026.115778_bb0830","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf600","article-title":"Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid-siRNA conjugate administered into cerebrospinal fluid","volume":"53","author":"Sorets","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2026.115778_bb0835","doi-asserted-by":"crossref","first-page":"114226","DOI":"10.1016\/j.jconrel.2025.114226","article-title":"Intravenous Lipid-siRNA Conjugate Mediates Gene Silencing at the Blood-Brain Barrier and Blood-CSF Barrier","volume":"387","author":"Sorets","year":"2025","journal-title":"J Control Release"},{"issue":"Part 2","key":"10.1016\/j.addr.2026.115778_bb0840","article-title":"The emerging role of microglia in the development and therapy of multiple sclerosis","volume":"143","author":"Nan","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.addr.2026.115778_bb0845","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/j.ymthe.2022.02.019","article-title":"Regulation of activated microglia and macrophages by systemically administered DNA\/RNA heteroduplex oligonucleotides","volume":"30","author":"Nishi","year":"2022","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.addr.2026.115778_bb0850","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ymthe.2024.03.004","article-title":"Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke","volume":"32","author":"Nong","year":"2024","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0855","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.ymthe.2023.01.016","article-title":"Preferential delivery of lipid-ligand conjugated DNA\/RNA heteroduplex oligonucleotide to ischemic brain in hyperacute stage","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"issue":"24","key":"10.1016\/j.addr.2026.115778_bb0860","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115778_bb0865","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jconrel.2023.07.027","article-title":"Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks","volume":"360","author":"Aly","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115778_bb0870","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2024.01.011","article-title":"Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease","volume":"367","author":"Caron","year":"2024","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.addr.2026.115778_bb0875","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/nn.4165","article-title":"G9a is essential for epigenetic silencing of K+ channel genes in acute-to-chronic pain transition","volume":"18","author":"Laumet","year":"2015","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0880","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1038\/s41598-019-39184-4","article-title":"Silencing of spinal Trpv1 attenuates neuropathic pain in rats by inhibiting CAMKII expression and ERK2 phosphorylation","volume":"9","author":"Guo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2026.115778_bb0885","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.omtn.2022.05.006","article-title":"Systemic DNA\/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve","volume":"28","author":"Kaburagi","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"11","key":"10.1016\/j.addr.2026.115778_bb0890","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1021\/acs.molpharmaceut.2c00523","article-title":"Peptides as pharmacological carriers to the brain: promises, shortcomings and challenges","volume":"19","author":"Parrasia","year":"2022","journal-title":"Mol. Pharm."},{"issue":"29","key":"10.1016\/j.addr.2026.115778_bb0895","doi-asserted-by":"crossref","first-page":"8406","DOI":"10.1016\/j.biomaterials.2014.06.003","article-title":"Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery","volume":"35","author":"Tagalakis","year":"2014","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.addr.2026.115778_bb0900","doi-asserted-by":"crossref","DOI":"10.3390\/polym14040712","article-title":"Angiopep-2-modified nanoparticles for brain-directed delivery of therapeutics: a review","volume":"14","author":"Habib","year":"2022","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.addr.2026.115778_bb0905","first-page":"2","article-title":"In silico immunogenicity assessment for sequences containing unnatural amino acids: a method using existing in silico algorithm infrastructure and a vision for future enhancements","author":"Mattei","year":"2022","journal-title":"Front. Drug Discov. (Lausanne)"},{"key":"10.1016\/j.addr.2026.115778_bb0910","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jconrel.2024.01.067","article-title":"E3MPH16: an efficient endosomolytic peptide for intracellular protein delivery","volume":"367","author":"Kawaguchi","year":"2024","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0915","first-page":"1","article-title":"Challenges and solutions for the downstream purification of therapeutic proteins","volume":"7","author":"Tang","year":"2024","journal-title":"Antib. Ther."},{"key":"10.1016\/j.addr.2026.115778_bb0920","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fbioe.2019.00420","article-title":"Recent developments in bioprocessing of recombinant proteins: expression hosts and process development","volume":"7","author":"Tripathi","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"15","key":"10.1016\/j.addr.2026.115778_bb0925","doi-asserted-by":"crossref","first-page":"10243","DOI":"10.1074\/jbc.M511572200","article-title":"Identification of the segments of the mouse transferrin receptor 1 required for mouse mammary tumor virus infection","volume":"281","author":"Wang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.addr.2026.115778_bb0930","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1007\/s00204-021-03115-y","article-title":"Differences in P-glycoprotein activity in human and rodent blood-brain barrier assessed by mechanistic modelling","volume":"95","author":"Verscheijden","year":"2021","journal-title":"Arch. Toxicol."},{"issue":"7\u20138","key":"10.1016\/j.addr.2026.115778_bb0935","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1101\/gad.309823.117","article-title":"Bridging barriers: a comparative look at the blood-brain barrier across organisms","volume":"32","author":"O'Brown","year":"2018","journal-title":"Genes Dev."},{"key":"10.1016\/j.addr.2026.115778_bb0940","first-page":"1","article-title":"Measurement variability of blood-brain barrier permeability using dynamic contrast-enhanced magnetic resonance imaging","volume":"2","author":"Varatharaj","year":"2024","journal-title":"Imaging Neurosci. (Camb.)"},{"key":"10.1016\/j.addr.2026.115778_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2020.103533","article-title":"Models of the blood-brain barrier using iPSC-derived cells","volume":"107","author":"Delsing","year":"2020","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.addr.2026.115778_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119980","article-title":"Vascularized neural constructs for ex-vivo reconstitution of blood-brain barrier function","volume":"245","author":"Yue","year":"2020","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0955","doi-asserted-by":"crossref","first-page":"15844","DOI":"10.1038\/s41598-024-66897-y","article-title":"Predicting blood-brain barrier permeability of molecules with a large language model and machine learning","volume":"14","author":"Huang","year":"2024","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.addr.2026.115778_bb0960","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2021.1904773","article-title":"Surface charge, glycocalyx, and blood-brain barrier function","volume":"9","author":"Walter","year":"2021","journal-title":"Tissue Barriers"},{"issue":"8056","key":"10.1016\/j.addr.2026.115778_bb0965","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41586-025-08589-9","article-title":"Glycocalyx dysregulation impairs blood-brain barrier in ageing and disease","volume":"639","author":"Shi","year":"2025","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.addr.2026.115778_bb0970","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.neuron.2022.04.011","article-title":"Matrix proteins plug a hole: how pericytes suppress blood brain barrier transcytosis","volume":"110","author":"Trevino","year":"2022","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb0975","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12987-021-00255-2","article-title":"Reduction in pericyte coverage leads to blood-brain barrier dysfunction via endothelial transcytosis following chronic cerebral hypoperfusion","volume":"18","author":"Sun","year":"2021","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"10.1016\/j.addr.2026.115778_bb0980","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neuron.2010.09.043","article-title":"Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging","volume":"68","author":"Bell","year":"2010","journal-title":"Neuron"},{"issue":"558","key":"10.1016\/j.addr.2026.115778_bb0985","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz6100","article-title":"Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome","volume":"12","author":"Han","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2026.115778_bb0990","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ebiom.2016.05.011","article-title":"Upregulation of Haploinsufficient gene expression in the brain by targeting a long non-coding RNA improves seizure phenotype in a model of Dravet syndrome","volume":"9","author":"Hsiao","year":"2016","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.addr.2026.115778_bb0995","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41591-020-0986-1","article-title":"Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 batten disease","volume":"26","author":"Centa","year":"2020","journal-title":"Nat. Med."},{"issue":"20","key":"10.1016\/j.addr.2026.115778_bb1000","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf1141","article-title":"Therapeutic antisense oligonucleotide mitigates retinal dysfunction in a pig model of CLN3 batten disease","volume":"53","author":"Stratton","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.addr.2026.115778_bb1005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41582-019-0211-3","article-title":"Antisense oligonucleotide reduces mutant protein in patients with HD","volume":"15","author":"Lempriere","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.addr.2026.115778_bb1010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/1061186X.2016.1207648","article-title":"Anti-cancer effect of R3V6 peptide-mediated delivery of an anti-microRNA-21 antisense-oligodeoxynucleotide in a glioblastoma animal model","volume":"25","author":"Oh","year":"2017","journal-title":"J. Drug Target."},{"issue":"6A","key":"10.1016\/j.addr.2026.115778_bb1015","first-page":"3785","article-title":"Antisense to integrin alpha v inhibits growth and induces apoptosis in medulloblastoma cells","volume":"21","author":"MacDonald","year":"2001","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.addr.2026.115778_bb1020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010090","article-title":"MiR-155: an important regulator of neuroinflammation","volume":"23","author":"Zingale","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115778_bb1025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.omtn.2022.11.005","article-title":"Decoding microRNAs in autism spectrum disorder","volume":"30","author":"Li","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.addr.2026.115778_bb1030","article-title":"The emerging role of long non-coding RNAs in schizophrenia","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Psychol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:32:16Z","timestamp":1782189136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26000128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":206,"alternative-id":["S0169409X26000128"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115778","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115778"}}